Biotech/Medical Tech Stock News from Investorideas.com

Friday, September 25, 2020

#Telemedicine #Stocks to Watch - (OTCPINK: $GTCH) (NYSE: $TDOC) (NYSE: $HUM) (TSXV: $DOC.V) (NasdaqGS: $LVGO) @GbtTechnologies @TeladocHealth @Humana @Livongo @CloudMD_SS

#Telemedicine #Stocks to Watch - (OTCPINK: $GTCH) (NYSE: $TDOC) (NYSE: $HUM) (TSXV: $DOC.V) (NasdaqGS: $LVGO) @GbtTechnologies @TeladocHealth @Humana @Livongo @CloudMD_SS

#COVID19 and the Accelerating Rise of Telemedicine

Point Roberts WA, Delta BC, September 25, 2020 Investorideas.com, a global news source and leading retail investor and trader resource issues a sector snapshot looking at the growing telemedicine market and participating public companies rising to meet the needs of innovation in healthcare, including GBT Technologies Inc. (OTCPINK:GTCH).

Read this news, featuring GTCH in full at https://www.investorideas.com/news/2020/biotech/09251Telemedicine-Stocks.asp

Telemedicine – the practice of providing or distributing healthcare-related services and information remotely, through digital and telecommunications technology means – is one of the fortunate industries to have risen in significance during the COVID-19 pandemic. The reasons for this are perhaps not difficult to guess. The prominence of social distancing guidelines and more particularly, the widespread policy (or advocacy for) quarantining has made traditional visits to clinics and hospitals more difficult. And in the months since the COVID-19 outbreak, this has been exacerbated at times by the delaying and postponing of non-emergent care. Naturally, this has led to the benefits of telemedicine, such as the ability to long-distant diagnose, inform, and monitor patients, making it even more relevant during this pandemic.

This is not to give the impression however, that telemedicine would not have become a consequential market regardless of a crisis like COVID-19. According to a report published before COVID-19, from Fortune Business Insights, the global market for telemedicine was valued at USD $34.28 billion in 2018, and is projected to reach USD $185.66 billion by 2026, making for a compound annual growth rate (CAGR) of 23.5 percent in the forecast period (2019-2026). But similar to other markets, like digital retail, telemedicine was already gaining traction and was well-positioned to meet the increasing demand brought on by the virus.

Like many emerging industries, the telemedicine space is seeing the surfacing of a panoply of different solutions. This is exemplified by qTerm, an AI-powered human vitals device from GBT Technologies Inc. (OTCPINK:GTCH) and its Joint Venture GBT Tokenize Corp. According to a recent press release, the qTerm device “is targeted to measure body temperature, blood pressure, and heart rate – all with a simple touch of the finger.” The device is deliberately small, able to be “be easily attached to a smart phone,” and coupled with an app, stores “a history for the user's records and provide numerical and statistical data about the user's body temperature.” This is enhanced further, as the devices AI anonymously and securely collects the user data, constructing a global ‘thermal map’ to alert about potential health risks proximities.

"This is the key highlight of the device," said Danny Rittman, CTO of GBT Technologies Inc. in a recent interview about qTerm. “Every person is going to be put on the world map for the benefit of the community."

In a recent interview with Capital Market Laboratories (CMLviz), Livongo Health, Inc. (NasdaqGS:LVGO) CEO, Zane M. Burke affirmed this, saying: “before the COVID, we had a ton of momentum.” But Burke also explained that, with the pandemic, people caught on to the advantages in the technology:

“…what occurred here is really everybody recognized first, the value of tele-health.”

He continued:

“The second part of this is remote patient monitoring became really meaningful, both from a regulatory and reimbursement perspective, as well as sort of people waking up to hey, the future of healthcare is going to be consumer directed virtual care.”

More recently, Livongo and telemedicine giant Teladoc Health, Inc. (NYSE:TDOC) filed a definitive proxy statement and prospectus with the US Securities and Exchange Commission (SEC) with regard to a proposed merger of the two firms. According to the press release, the two companies plan to “provide a consumer centered virtual care platform for the full spectrum of health needs, creating a new standard in global healthcare delivery, access and an improved consumer experience.”

Another approach is that of healthcare and well-being firm Humana Inc. (NYSE:HUM) which recently announced an expanded relationship with tech-enabled health services company, Seniorlink, Inc. The collaboration will see Humana leverage Seniorlink’s digital care collaboration platform Vela, to support its vulnerable, high risk members by “increasing the overall engagement and reducing barriers to contact between members and care managers.” Tom Riley, President and CEO of Seniorlink, said:

"The COVID-19 crisis has prompted the healthcare industry to re-imagine care delivery for our country's most vulnerable. By leveraging Vela, more of Humana's high-risk members will have access to their integrated care team in one platform. This is particularly advantageous at a time when many members want to access care from home."

In addition to the various approaches employed to contend with COVID-19, the space has seen individual firms enjoy massive growth in the wake of the pandemic. Software-as-a-service (SaaS) based health technology solutions provider CloudMD Software & Services Inc. (TSXV:DOC) recently reported a year-over-year total revenue increase from Q2 2019 to Q2 2020. Notably, the company saw “gross margins of 42% due to higher margin verticals and increase in telehealth usage,” according to the press release. The company’s CEO, Essam Hamza, in discussing his own firm’s success amidst the pandemic, provided a microcosm of the wider market:

“We are currently in the worst public health crisis of our lifetime and as a front line physician for over 20 years I acutely understand the toll it is taking on our healthcare system and the importance of access to quality health care. Our CloudMD platform is well equipped to increase access through the availability of our seamless virtual care solutions that allow patients to access quality health care from anywhere.”

Telemedicine’s utility extends beyond the current pandemic, as demonstrated by the pre-COVID projections in the aforementioned research published by Fortune Business Insights. In fact, an article published by the International Journal of Health Policy and Management (IJHPM), titled: Climate Change and Telemedicine: A Prospective View, argues that it can be beneficial in the context of climate crisis as well. This is not only manifested in its application in treating climate change’s many effects on public health as outlined by the CDC, but the IJHPM article points out the reduction of unnecessary travel and its resulting emissions that adopting telemedicine would achieve. An excerpt reads:

In another study, conducted in Canada, a wide range of healthcare services were provided in the form of teleconsultation and as a result road trips were reduced by 757 234 km, and transport vehicle carbon dioxide emissions were reduced by 185 tons.

Similar to the transformation in the retail sector toward digital technology, the long-distance interactions that telemedicine facilitates already showed tremendous promise, but the COVID-19 pandemic has accelerated its growth and seems to have assured its endurance.

For a list of telemedicine stocks visit here.

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: GTCH is a paid monthly featured company for news and social media on Investorideas.com More disclaimer info: https://www.investorideas.com/About/Disclaimer.aspLearn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on Investorideas.com

Get more tech stocks investor ideas- news, articles, podcasts and stock directories

Friday, September 18, 2020

Investor Ideas Adds New Biotech (Nasdaq: $ACER) (Nasdaq: $AIKI) (Nasdaq: $JAN) (TSXV: $MDP.V) and Gaming/eSport Stocks (Nasdaq: $SLGG)

Investor Ideas Adds New Biotech (Nasdaq: $ACER) (Nasdaq: $AIKI) (Nasdaq: $JAN) (TSXV: $MDP.V) and Gaming/eSport Stocks (Nasdaq: $SLGG)

Point Roberts WA, Delta BC, September 18, 2020 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading retail investor resource announces its weekly roundup of stocks added to its free global stock directories; biotech, gaming and eSport.

Read this news in full at https://www.investorideas.com/news/2020/main/09181Stocks.asp

The newest biotech companies are involved in a variety of pharmaceutical and medical device products as well as life sciences and healthcare products and services, including some related to Coronavirus (COVID-19).

The latest gaming/eSport companies include a leading gaming community and content platform and the latest gaming indice - MVIS Global Video Gaming & eSports (AUD) Index (MVESPOA).

New stocks added to Biotech stocks directory

Acer Therapeutics (NasdaqGS:ACER) is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant for the treatment of induced Vasomotor Symptoms (iVMS). Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA.

AIkido Pharma Inc. (NasdaqGS:AIKI) was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Annovis Bio (NYSE American:ANVS) Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and have commenced a second Phase 2a study in AD and PD patients.

Aptorum Group Limited (NasdaqGM:APM) is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers (including orphan oncology indications). The pipeline of Aptorum is also enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. In addition to the above main focus, we are also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women’s health and other disease areas. We also have projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.

Arcturus Therapeutics (NasdaqGM:ARCT) ounded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation

Artelo Biosciences, Inc. (NasdaqGS:ARTL) is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system and related pathways. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies.

JanOne Inc. (NasdaqGS:JAN) is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions and neuropathic pain. JanOne continues to operate its legacy businesses under their current brand names, which are undergoing review to determine appropriate strategic alternatives.

Medexus Pharmaceuticals Inc. (TSX:MDP.V) is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative allergy medication with a unique mode of action.

American Shared Hospital Services (NYSE American:AMS) provides turnkey technology solutions for advanced radiosurgical and radiation therapy services. AMS is a world leader in providing Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations, and trigeminal neuralgia (facial pain). The Company also offers proton therapy, and the latest IGRT, IMRT and MR/LINAC systems.

Zynex, Inc. (NasdaqGS:ZYXI) founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the Company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers.

New stocks added to Gaming/eSports stocks directory

MVIS Global Video Gaming & eSports (AUD) Index (MVESPOA) is a pure play index that tracks the performance of global companies that generate at least 50% of their revenues (25% for current components) from the video gaming and eSports sector. These companies may include those that develop video games and related software/hardware, streaming services, and are involved in eSports events.

Super League Gaming (NasdaqGS:SLGG) is a leading gaming community and content platform that gives everyday gamers multiple ways to connect and engage with others while enjoying the video games they love. Powered by patented, proprietary technology systems, Super League offers players the ability to create gameplay-driven experiences they can share with friends, the opportunity to watch live streaming broadcasts and gameplay highlights across digital and social channels, and the chance to compete in events and challenges designed to celebrate victories and achievements across multiple skill levels. With gameplay and content offerings featuring more than a dozen of the top video game titles in the world, Super League is building a broadly inclusive, global brand at the intersection of gaming, experiences and entertainment. Whether to access its expanding direct audience or the company’s unique content production and virtual event capabilities, third parties ranging from consumer brands, video game publishers, television companies, traditional sports organizations, concert promoters, and more, are turning to Super League to provide integrated solutions that drive business growth.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news and press releases, research and our own original financial content. We were one of the first retail investor sites to cover renewable energy and cleantech stocks at investorideas.com and our domain Renewableenergystocks.com. We were also one of the most well- known and cited defense stock sites, featuring our domain Homelanddefensestocks.com at its peak.

We follow the money for investors as sector sentiment shifts and technology disrupts. Our mission is to provide investor ideas with breaking news, resources, industry articles and interviews with leading experts.

Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining and the AI Eye.

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Friday, September 11, 2020

Former CEO of Aethlon Medical, (NASDAQ: $AEMD) Leads new #Medtech Company Sigyn Therapeutics; Company Merges into Reign Resources Corporation (OTCMARKETS: $RGNP)

Former CEO of Aethlon Medical, (NASDAQ: $AEMD) Leads new #Medtech Company Sigyn Therapeutics; Company Merges into Reign Resources Corporation (OTCMARKETS: $RGNP)

LOS ANGELES, CA, September 11, 2020 (Investorideas.com newswire) Breaking Medical Tech/ Covid- 19 stock news - Reign Resources Corporation (“Reign”) (OTCMARKETS: RGNP) announced today that the Company has approved a share exchange agreement with Sigyn Therapeutics, Inc., a privately held medical technology company focused on the treatment of life-threatening inflammatory conditions. As reported in a Schedule 14C Information statement filed today with the U.S. Securities and Exchange Commission (SEC) and a Form 8-K filed on August 31, 2020, Reign resources will acquire all of the outstanding capital stock of Sigyn Therapeutics in exchange for shares of Reign common stock representing approximately 75 percent of Reign’s outstanding common stock. The Schedule 14C Information statement and Form 8-K can be accessed at www.SEC.gov.

Read this news, featuring RGNP in full at https://www.investorideas.com/news/2020/biotech/09111RGNP-AEMD-Sigyn-Therapeutics.asp

Upon completion of the merger, Reign will be renamed Sigyn Therapeutics, Inc. and will be led by Sigyn co-founder Jim Joyce, who will serve as Chairman and CEO of the combined company. Sigyn Therapeutics will be focused on addressing a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome (“The Cytokine Storm” or “CSS”) and not addressed with an approved therapy. The annual market opportunity for a therapeutic strategy to prevent or mitigate CSS has been reported to exceed $20 billion. Additional announcements regarding the combined company’s management structure, Board of Directors and Science Advisory Board will be forthcoming.

Sigyn Therapy™ is a development-stage blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory conditions, including sepsis, which is the #1 cause of hospital deaths. The mechanism of Sigyn Therapy allows for a broad-spectrum of inflammatory targets to be depleted from the bloodstream. Among the targets are inflammatory cytokines, cytokine aggregates, endotoxin and CytoVesicles that transport cytokines and other inflammatory cargos.

Beyond sepsis, Cytokine Storm related therapeutic opportunities include, but are not limited to virus induced Cytokine Storm (a leading cause of COVID-19 deaths), bacteria induced Cytokine Storm, acute respiratory distress syndrome (ARDS) and acute forms of liver failure, including hepatic encephalopathy. Sigyn Therapy may also be a candidate to stabilize or extend the life of patients waiting for the identification of a matched liver for transplantation. In such a scenario, Sigyn Therapy™ would serve as a bridge-to-liver transplant. Cytokine Storm Syndrome can also result from trauma, severe burns, acute pancreatitis, adverse drug reactions, cancer immunotherapies, cancer cachexia, acute kidney injury (AKI) and severe pneumonia.

Other Corporate Highlights

· Sigyn’s co-founders have 50+ years of experience in the medical technology field and played instrumental roles in the development of three technologies that have been cleared by the FDA to treat COVID-19 infected individuals.

· Jim Joyce, the Chairman and CEO of Sigyn Therapeutics, has two decades of public company CEO and Board leadership experience. Specific to therapeutic blood purification, Mr. Joyce was the founder, Chairman and CEO of Aethlon Medical, ( NASDAQ: AEMD) a company that he navigated from a single shareholder start-up to Nasdaq-traded Company with 8,000+ shareholders.

· Sigyn Therapy aligns with U.S. government initiatives to support broad-spectrum treatment countermeasures that mitigate life-threatening conditions resulting from pandemic outbreaks such as COVID-19.

· A deep pipeline of pre-clinical, clinical and regulatory milestones are planned over the next 12-18 months.

About Sigyn Therapeutics

Sigyn Therapeutics is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

Sigyn Therapy™ is a patent pending blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

To learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com

About Reign Resources Corporation

Reign Resources Corp. is a Los Angeles-based, gold exploration company with a specific focus on the Bendigo & Ballarat regions in Victoria, Australia.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of Reign Resources Corporation. (“Reign”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Reign’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Reign’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Reign makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Reign’s business and the price of the common stock of Reign, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Reign’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to uplist to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Reign’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) the outcome of any legal proceedings that may be instituted against Reign related to the merger agreement or the transaction. Further risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements are discussed in “Risk Factors” and elsewhere in Reign’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and other reports filed with the SEC. The forward-looking statements in this press release represent Reign’s views as of the date of this press release. Reign anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Reign’s views as of any date subsequent to the date of this press release.

Contact Reign Resources Corporation

Joseph Segelman

CEO

(213) 457 3772

info@reignsc.com

Contact Sigyn Therapeutics, Inc.

Jim Joyce

Chairman, CEO

(619) 368-2000

jimjoyce@elevatescience.com

Investorideas.com Paid news Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: this news release featuring (OTCMARKETS: RGNP) is a paid for news release on Investorideas.com https://www.investorideas.com/News-Upload/ More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please Read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

About Investorideas.com

https://www.investorideas.com/About/

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp